.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cipla
Federal Trade Commission
Johnson and Johnson
UBS
Cantor Fitzgerald
Julphar
Argus Health
Mallinckrodt
Chinese Patent Office
Citi

Generated: July 27, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 019012

« Back to Dashboard
NDA 019012 describes NUPRIN, which is a drug marketed by J And J Consumer Inc and Bristol Myers and is included in three NDAs. It is available from four suppliers. Additional details are available on the NUPRIN profile page.

The generic ingredient in NUPRIN is ibuprofen. There are sixty-four drug master file entries for this compound. Two hundred and fifty-five suppliers are listed for this compound. Additional details are available on the ibuprofen profile page.

Summary for NDA: 019012

Tradename:
3
Applicant:
1
Ingredient:
1
Patents:0
Therapeutic Class:Analgesics
Anti-inflammatory Agents
Formulation / Manufacturing:see details

Suppliers and Packaging for NDA: 019012

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
MOTRIN IB
ibuprofen
TABLET;ORAL 019012 NDA Mechanical Servants, LLC 29485-1465 29485-1465-4 2 POUCH in 1 PACKAGE (29485-1465-4) > 2 TABLET, FILM COATED in 1 POUCH
MOTRIN IB
ibuprofen
TABLET;ORAL 019012 NDA Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division 50580-110 50580-110-02 1 BOTTLE, PLASTIC in 1 CARTON (50580-110-02) > 50 TABLET, FILM COATED in 1 BOTTLE, PLASTIC

Summary for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:TABLET;ORALStrength200MG
Approval Date:May 18, 1984TE:RLD:No

Summary for product number 002

Active Rx/OTC/Discontinued:DISCNDosage:TABLET;ORALStrength200MG
Approval Date:Jul 29, 1987TE:RLD:No

Summary for product number 003

Active Rx/OTC/Discontinued:OTCDosage:TABLET;ORALStrength200MG
Approval Date:Dec 17, 1990TE:RLD:Yes


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Dow
Novartis
Harvard Business School
Argus Health
Accenture
Chinese Patent Office
UBS
Johnson and Johnson
Farmers Insurance
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot